{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pandey B"],"funding":["Georgia Tech Foundation","Robert A. Milton Chaired Professorship to Krishnendu Roy","NIAID NIH HHS","National Institutes of Health- National Institute of Allergy and Infectious Disease"],"pagination":["e2402792"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11615772"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(45)"],"pubmed_abstract":["Existing parenteral SARS-CoV-2 vaccines produce only limited mucosal responses, essential for reducing transmission and achieving sterilizing immunity. Appropriately designed mucosal boosters can overcome the shortcomings of parenteral vaccines and enhance pre-existing systemic immunity. Here, a new protein subunit nanovaccine is developed by utilizing dual-adjuvanted (RIG-I: PUUC RNA and TLR-9: CpG DNA) polysaccharide-amino acid-lipid nanoparticles (PAL-NPs) along with SARS-CoV-2 S1 trimer protein, that can be delivered both intramuscularly (IM) and intranasally (IN) to generate balanced mucosal-systemic SARS-CoV-2 immunity. Mice receiving IM-Prime PUUC+CpG PAL subunit nanovaccine, followed by an IN-Boost, developed high levels of IgA, IgG, and cellular immunity in the lungs and showed ro"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice."],"pmcid":["PMC11615772"],"funding_grant_id":["U01 AI124270","U01-AI124270"],"pubmed_authors":["Jain R","O'Farrell L","Hur D","Maniar D","Smith C","Ochoa MA","Hosten J","Ringquist R","Jimenez A","Roy K","Bhatia E","Pandey B","Wang Z","Beach A","Vantucci C","Noel R"],"additional_accession":[]},"is_claimable":false,"name":"A Dual-Adjuvanted Parenteral-Intranasal Subunit Nanovaccine generates Robust Systemic and Mucosal Immunity Against SARS-CoV-2 in Mice.","description":"Existing parenteral SARS-CoV-2 vaccines produce only limited mucosal responses, essential for reducing transmission and achieving sterilizing immunity. Appropriately designed mucosal boosters can overcome the shortcomings of parenteral vaccines and enhance pre-existing systemic immunity. Here, a new protein subunit nanovaccine is developed by utilizing dual-adjuvanted (RIG-I: PUUC RNA and TLR-9: CpG DNA) polysaccharide-amino acid-lipid nanoparticles (PAL-NPs) along with SARS-CoV-2 S1 trimer protein, that can be delivered both intramuscularly (IM) and intranasally (IN) to generate balanced mucosal-systemic SARS-CoV-2 immunity. Mice receiving IM-Prime PUUC+CpG PAL subunit nanovaccine, followed by an IN-Boost, developed high levels of IgA, IgG, and cellular immunity in the lungs and showed ro","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T01:06:23.007Z","creation":"2025-04-04T01:06:23.007Z"},"accession":"S-EPMC11615772","cross_references":{"pubmed":["39352717"],"doi":["10.1002/advs.202402792"]}}